Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced it will showcase Genedata BiologicsTM at the Seventh Annual PEGS. Genedata Biologics, a first-in-class biologics data management and analysis platform, helps to advance biologics research and development. Recently released, it has already been adopted by several leading pharmaceutical and biotech companies. The software solution will be featured at PEGS in a Bayer Healthcare Pharmaceuticals presentation on Engineering Antibodies. It will also be showcased in a number of PEGS poster sessions spanning diverse applications in protein engineering, optimization and expression as well as specialized use cases such as engineering of bispecific antibodies. PEGS, the leading protein engineering summit, will be held at the Sheraton Boston Hotel, May 9 – 13.
“Biopharmaceuticals is the fastest growing market segment in the pharmaceutical industry; however, the discovery and development process for biologics molecules is extremely complex, labor intensive, and costly,” said Dr. Othmar Pfannes, CEO of Genedata. “With Genedata Biologics, we provide the first integrated platform supporting the entire biologics R&D process. The system allows the collection of all relevant experimental data generated along the biologics R&D process and makes these data available to all involved laboratories and project managers. Therefore, data and material handovers from lab-to-lab are greatly facilitated, and decision making is put onto a solid foundation based on experimental data. This helps to make our customers’ overall biologics discovery and development processes more efficient and ensures consistently high quality standards across different laboratories.”
Genedata Biologics Saves Millions in R&D Dollars
“Genedata Biologics makes biologics discovery more efficient and can easily save millions of R&D dollars,” continued Pfannes. Based on more than four years of development in close collaboration with international pharmaceutical and biotechnology customers, Genedata Biologics is an off-the-shelf software platform that allows the provisioning of focused solutions for specific parts of biologics R&D with modules that address:
Based on a comprehensive biologics registration infrastructure, the system comes with built-in engines to ensure uniqueness of biologics molecules and materials – for both proteins and antibodies; and classical as well as next-generation format molecules. These capabilities advance high-quality standards and avoid duplicated efforts. Providing easy data access for all biologics molecules and materials, the system provides flexible tools for naming, association, searching, retrieving, analyzing, and reporting.
With an Oracle®-based database infrastructure and a web-based front-end, the Genedata Biologics open design allows seamless interfacing and integration with existing corporate IT infrastructures and laboratory instruments. The system is equipped with a default configuration that minimizes set-up and customization efforts, and lowers implementation costs. Genedata Biologics can be easily configured to support corporate-specific variants of biologics R&D workflows such as handling of proprietary libraries, workflows, or molecule formats.
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery, industrial biotechnology, and life science research. Used by a majority of the world’s top 50 pharmaceutical companies and leading research organizations, Genedata solutions make research data accessible and understandable, enabling scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Japan, Germany, and the US. www.genedata.com
Marketing & Communications
Phone: +41 61 511 8459
Phone: +1 508 881 3109
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.